MSTX – Mast Therapeutics, Inc.

Mast Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for serious or life-threatening diseases. Its lead product candidate includes MST-188, a product candidate that has hemorheologic, cytoprotective, and anti-inflammatory properties, which is in phase 3 study for the treatment of sickle cell disease in patients. The company was formerly known as ADVENTRX Pharmaceuticals, Inc. and changed its name to Mast Therapeutics, Inc. in March 2013. Mast Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

What stocks to buy now?

The following small cap stocks  feature high cash on the books, often worth close to or greater than the market value of the entire company, with little or no debt to speak of. Given these parameters, if these companies were liquidated today, an investor would get his or her money back and then some. When [...]